Pluri Announced €1M Proof Of Concept Agreement To Enhance Global Sustainable Vegetable Supply

7/8/24 7:06:24 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $PLUR alert in real time by email

Pluri Inc. (NASDAQ:PLUR) (TASE:PLUR) ("Pluri" or "the Company"), which transforms cells into solutions that promote global wellbeing and sustainability, has announced a strategic proof of concept ("POC") agreement with a leading international agriculture corporation. The agreement is intended to boost the global vegetable product supply, streamline supply chains, and combat global climate change while ensuring a natural and more sustainable future for agriculture.

Get the next $PLUR alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$PLUR

Date	Price Target	Rating	Analyst

More analyst ratings

Pluri Inc. to Present at November 21st Virtual Investor Summit Microcap Event
HAIFA, ISRAEL / ACCESSWIRE / November 12, 2024 / Pluri Inc. (NASDAQ:PLUR), a leading biotechnology company that offers cell-based solutions for various industries. The company will be available for 1-on-1 meetings throughout the day in addition to their presentation.Event: Q4 Investor SummitPresentation Time: 9:00am - 9:30am ETLocation: https://www.webcaster4.com/Webcast/Page/3075/51643The theme is 40 micro-cap companies with a catalyst and/or strong performance in the current market.Take a deep dive with the best Investors in MicroCapLive Q & AComplimentary to Qualified Investors. Please REGISTER HERE.About the Investor SummitThe Investor Summit is an exclusive, independent conference dedic
11/12/24 1:00:00 PM ET
$PLUR
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing
Memorandum of Understanding has been signed NEW YORK, Nov. 11, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that it has entered into a Memorandum of Understanding (MOU) with Pluri Inc. (NASDAQ:PLUR) through its wholly owned subsidiary ("Pluri"), an established global leader in the development and manufacturing of cell-based therapeutics, to manufacture NurOwn® for use in BrainStorm's planned Phase 3b trial in amyotrophic lateral sclerosis (ALS). This MOU enables BrainStorm to begin transfer of its manufacturing technology and start producing NurOwn at Pluri's manufacturing facil
11/11/24 6:00:00 AM ET
$BCLI
$PLUR
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Pluri Collaborates with Bar-Ilan University to Advance Cancer Immunotherapy for Solid Tumors, Supported by Israel Innovation Authority
The Israel Innovation Authority will fund Pluri and BIRAD's collaboration to advance MAIT Cell Therapy, led by Professor Cyrille Cohen, Head of the laboratory of tumor immunology and immunotherapy at Bar-Ilan UniversityMAIT cells hold immense potential for immunotherapy and the treatment of solid tumors compared to conventional T-cells, but their expansion has been a challenge until Pluri announced its proprietary MAIT immunotherapy platform in May 2024Global cancer immunotherapy market is expected to reach $312 billion by 2033 HAIFA, Israel, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (NASDAQ:PLUR) (TASE:PLUR) ("Pluri" or the "Company"), a leading biotechnology company that tran
10/28/24 7:00:00 AM ET
$PLUR
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Pluri Announced €1M Proof Of Concept Agreement To Enhance Global Sustainable Vegetable Supply

Chat with this insight

Recent Analyst Ratings for
$PLUR

$PLUR
Financials

Live finance-specific insights

BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing

$PLUR
Market Insights

Live Market Insights

Pluri Partners with Kadimastem to Advance Cell Therapy Products for Clinical Trials